| Title |
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
|
|---|---|
| Published in |
Science Translational Medicine, March 2022
|
| DOI | 10.1126/scitranslmed.abn7842 |
| Pubmed ID | |
| Authors |
Benjamin L Sievers, Saborni Chakraborty, Yong Xue, Terri Gelbart, Joseph C Gonzalez, Arianna G Cassidy, Yarden Golan, Mary Prahl, Stephanie L Gaw, Prabhu S Arunachalam, Catherine A Blish, Scott D Boyd, Mark M Davis, Prasanna Jagannathan, Kari C Nadeau, Bali Pulendran, Upinder Singh, Richard H Scheuermann, Matthew B Frieman, Sanjay Vashee, Taia T Wang, Gene S Tan |
| Abstract |
Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that possess mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. Although the current vaccines have largely been effective against past variants, the number of mutations found on the Omicron (B.1.1.529) spike protein appear to diminish the protection conferred by pre-existing immunity. Using vesicular stomatitis virus (VSV) pseudoparticles expressing the spike protein of several SARS-CoV-2 variants, we evaluated the magnitude and breadth of the neutralizing antibody response over time in individuals after infection and in mRNA-vaccinated individuals. We observed that boosting increases the magnitude of the antibody response to wildtype (D614), Beta, Delta, and Omicron variants; however, the Omicron variant was the most resistant to neutralization. We further observed that vaccinated healthy adults had robust and broad antibody responses whereas responses may have been reduced in vaccinated pregnant women, underscoring the importance of learning how to maximize mRNA vaccine responses in pregnant populations. Findings from this study show substantial heterogeneity in the magnitude and breadth of responses after infection and mRNA vaccination and may support the addition of more conserved viral antigens to existing SARS-CoV-2 vaccines. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 24 | 30% |
| Spain | 3 | 4% |
| Mexico | 3 | 4% |
| India | 3 | 4% |
| Italy | 2 | 3% |
| Indonesia | 1 | 1% |
| Netherlands | 1 | 1% |
| United Kingdom | 1 | 1% |
| Brazil | 1 | 1% |
| Other | 8 | 10% |
| Unknown | 32 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 62 | 78% |
| Scientists | 11 | 14% |
| Science communicators (journalists, bloggers, editors) | 3 | 4% |
| Practitioners (doctors, other healthcare professionals) | 3 | 4% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 80 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 18% |
| Student > Ph. D. Student | 11 | 14% |
| Student > Bachelor | 7 | 9% |
| Student > Doctoral Student | 3 | 4% |
| Professor | 3 | 4% |
| Other | 9 | 11% |
| Unknown | 33 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 14% |
| Immunology and Microbiology | 9 | 11% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Agricultural and Biological Sciences | 5 | 6% |
| Chemistry | 4 | 5% |
| Other | 12 | 15% |
| Unknown | 33 | 41% |